More than a third of patients on Wegovy pill are new to GLP-1 drugs, study finds

By Robin Respaut

SAN FRANCISCO, Feb 11 (Reuters) – Among ‌early users of Novo ‌Nordisk’snew Wegovy weight-loss pill, 36% ​had no prior experience taking a GLP-1 medication, a new study from ‌the health ⁠data firm Truveta found.

Of patients who started ⁠a new pill prescription, 21.1% had previously ​taken the injectable ​version ​of Wegovy ‌and 15.8% switched from Eli Lilly’s Zepbound, another injectable GLP-1 medicine, according to Truveta data.

Truveta reviewed health ‌records from 8,762 ​patients with ​evidence ​of a prescription ‌for the new Wegovy ​pill, ​which was approved by the U.S. Food and ​Drug ‌Administration on December 22.

(Reporting ​by Robin RespautEditing by ​Bill Berkrot)